Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Diarrhea 1Colitis 1Breast Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 13atezolizumab 7Ipilimumab 6Cyclophosphamide 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5aldesleukin 4Interleukin-2 4Biopsy 4durvalumab 3cemiplimab 3Docetaxel 3tislelizumab 2osimertinib 2fludarabine phosphate 2enzalutamide 2avelumab 2X-Rays 2Ritonavir 2Radiotherapy 2Observation 2Methods 2Immunoglobulin G 2IFL protocol 2Drug Therapy 2zimberelimab 1utomilumab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Loperamide × Dermatologic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡